

Product Datasheet

IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free NBP2-12364-0.025mg

Unit Size: 0.025 mg

Store at -20C. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 2

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-12364

Updated 9/9/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP2-12364



NBP2-12364-0.025mg

IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

Product Information	
Unit Size	0.025 mg
Concentration	LYOPH mg/ml
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Monoclonal
Clone	MM0342-6U23
Preservative	No Preservative
Reconstitution Instructions	Reconstitute with sterilized PBS to a final concentration of 0.5 mg/ml.
Isotype	IgG2
Purity	Protein G purified
Buffer	Lyophilized from a 0.2 um filtered solution in PBS. 0.025 mg size is provided in liquid form, PBS

Product Description	
Description	Novus Biologicals Mouse IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free (NBP2-12364) is a monoclonal antibody validated for use in IHC and WB. Anti-IGFBP-3 Antibody: Cited in 2 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Mouse
Gene ID	3486
Gene Symbol	IGFBP3
Species	Human
Immunogen	Human recombinant IGFBP-3



Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, Immunohistochemistry
Recommended Dilutions	Western Blot 1:500-1:2000, Immunohistochemistry 1:20-200, Immunohistochemistry-Paraffin 1:20-1:200
Application Notes	This IGFBP3 antibody (clone MM0342-6U23) is useful for Western Blot and Immunohistochemistry-Paraffin applications. In its IHC-P validation, the antigen retrieval was performed by incubation of sections with Proteinase K (20ug/ml in PBS) for 15min at room temperature (Note: the length of PK exposure should be optimized by the user as it may depend upon the variation of fixatives and length of fixation applied to a particular specimen).




Images

BoTA-induced endometrial regeneration mediated by IGFBP3-dependent OPN proteolytic cleavage in a thin endometrium mouse model A Venn diagram of DEGs from EtOH-treated vs. saline-treated uteri (GSE207379) and BoTA-treated vs. saline-treated (GSE146934) displaying a shared gene with a reciprocal expression; *Igfbp3*. B Gene-gene network analysis of DEGs of EtOH-treated vs. saline-treated uteri categorized in CC GO terms displaying a shared gene; *Spp1C* Immunoblotting analysis of IGFBP3 and OPN in BoTA-treated thin endometrium compared to saline-treated group. D Immunoblotting analysis of OPN in BoTA-treated thin endometrium compared to IGFBP3-treated thin endometrium. β -actin was used as a loading control. E An experimental schedule for an application of IGFBP3 neutralizing antibody together with BoTA. F Immunoblotting analysis of IGFBP3 and OPN in response to IGFBP3 neutralizing antibody treatment. β -actin was used as a loading control. G Immunostaining of IGFBP3 in saline-treated, BoTA-treated, and BoTA with IGFBP-3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of IGFBP3 in the whole region of uterus and the indicated region with a box is magnified in lower panel. Scale bar; 100 μ m. H Immunostaining of active-OPN in saline-treated, BoTA-treated, and BoTA with IGFBP3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of active-OPN in the whole region of uterus and the indicated regions (LE luminal epithelium, GE glandular epithelium) with boxes are magnified in lower panel. Scale bar: 100 μ m. I H&E images for saline-, BoTA-, and BoTA with IGFBP3 neutralizing antibody-treated uteri. Scale bar: 100 μ m Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36602651>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.


BoTA-induced endometrial regeneration mediated by IGFBP3-dependent OPN proteolytic cleavage in a thin endometrium mouse model A Venn diagram of DEGs from EtOH-treated vs. saline-treated uteri (GSE207379) and BoTA-treated vs. saline-treated (GSE146934) displaying a shared gene with a reciprocal expression; *Igfbp3*. B Gene-gene network analysis of DEGs of EtOH-treated vs. saline-treated uteri categorized in CC GO terms displaying a shared gene; *Spp1C* Immunoblotting analysis of IGFBP3 and OPN in BoTA-treated thin endometrium compared to saline-treated group. D Immunoblotting analysis of OPN in BoTA-treated thin endometrium compared to IGFBP3-treated thin endometrium. β -actin was used as a loading control. E An experimental schedule for an application of IGFBP3 neutralizing antibody together with BoTA. F Immunoblotting analysis of IGFBP3 and OPN in response to IGFBP3 neutralizing antibody treatment. β -actin was used as a loading control. G Immunostaining of IGFBP3 in saline-treated, BoTA-treated, and BoTA with IGFBP-3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of IGFBP3 in the whole region of uterus and the indicated region with a box is magnified in lower panel. Scale bar; 100 μ m. H Immunostaining of active-OPN in saline-treated, BoTA-treated, and BoTA with IGFBP3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of active-OPN in the whole region of uterus and the indicated regions (LE luminal epithelium, GE glandular epithelium) with boxes are magnified in lower panel. Scale bar: 100 μ m. I H&E images for saline-, BoTA-, and BoTA with IGFBP3 neutralizing antibody-treated uteri. Scale bar: 100 μ m Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36602651>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



BoTA-induced endometrial regeneration mediated by IGFBP3-dependent OPN proteolytic cleavage in a thin endometrium mouse model A Venn diagram of DEGs from EtOH-treated vs. saline-treated uteri (GSE207379) and BoTA-treated vs. saline-treated (GSE146934) displaying a shared gene with a reciprocal expression; *Igfbp3*. B Gene-gene network analysis of DEGs of EtOH-treated vs. saline-treated uteri categorized in CC GO terms displaying a shared gene; *Spp1c* Immunoblotting analysis of IGFBP3 and OPN in BoTA-treated thin endometrium compared to saline-treated group. D Immunoblotting analysis of OPN in BoTA-treated thin endometrium compared to IGFBP3-treated thin endometrium. β -actin was used as a loading control. E An experimental schedule for an application of IGFBP3 neutralizing antibody together with BoTA. F Immunoblotting analysis of IGFBP3 and OPN in response to IGFBP3 neutralizing antibody treatment. β -actin was used as a loading control. G Immunostaining of IGFBP3 in saline-treated, BoTA-treated, and BoTA with IGFBP-3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of IGFBP3 in the whole region of uterus and the indicated region with a box is magnified in lower panel. Scale bar; 100 μ m. H Immunostaining of active-OPN in saline-treated, BoTA-treated, and BoTA with IGFBP3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of active-OPN in the whole region of uterus and the indicated regions (LE luminal epithelium, GE glandular epithelium) with boxes are magnified in lower panel. Scale bar: 100 μ m. I H&E images for saline-, BoTA-, and BoTA with IGFBP3 neutralizing antibody-treated uteri. Scale bar: 100 μ m Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36602651>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



BoTA-induced endometrial regeneration mediated by IGFBP3-dependent OPN proteolytic cleavage in a thin endometrium mouse model A Venn diagram of DEGs from EtOH-treated vs. saline-treated uteri (GSE207379) and BoTA-treated vs. saline-treated (GSE146934) displaying a shared gene with a reciprocal expression; *Igfbp3*. B Gene-gene network analysis of DEGs of EtOH-treated vs. saline-treated uteri categorized in CC GO terms displaying a shared gene; *Spp1c* Immunoblotting analysis of IGFBP3 and OPN in BoTA-treated thin endometrium compared to saline-treated group. D Immunoblotting analysis of OPN in BoTA-treated thin endometrium compared to IGFBP3-treated thin endometrium. β -actin was used as a loading control. E An experimental schedule for an application of IGFBP3 neutralizing antibody together with BoTA. F Immunoblotting analysis of IGFBP3 and OPN in response to IGFBP3 neutralizing antibody treatment. β -actin was used as a loading control. G Immunostaining of IGFBP3 in saline-treated, BoTA-treated, and BoTA with IGFBP-3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of IGFBP3 in the whole region of uterus and the indicated region with a box is magnified in lower panel. Scale bar; 100 μ m. H Immunostaining of active-OPN in saline-treated, BoTA-treated, and BoTA with IGFBP3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of active-OPN in the whole region of uterus and the indicated regions (LE luminal epithelium, GE glandular epithelium) with boxes are magnified in lower panel. Scale bar: 100 μ m. I H&E images for saline-, BoTA-, and BoTA with IGFBP3 neutralizing antibody-treated uteri. Scale bar: 100 μ m Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36602651>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Lee D, Ahn J, Koo HS, Kang YJ. Intrauterine botulinum toxin A administration promotes endometrial regeneration mediated by IGFBP3-dependent OPN proteolytic cleavage in thin endometrium Cellular and Molecular Life Sciences 2023-01-05 [PMID: 36602651] (Immunohistochemistry-Paraffin, Human)

Kim N, Kim HK, Lee K et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nat Commun 2020-05-08 [PMID: 32385277] (IHC-P, Human)





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-12364-0.025mg

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF007	Goat anti-Mouse IgG Secondary Antibody [HRP]
NB7539	Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP]
NBP2-35003-5ug	Recombinant Human IGFBP-3 Protein

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-12364

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

